Diabetes Therapy
European Commission approves Exubera for treatment of type 1 and type 2 diabetes
Published in Diabetes Week, February 20th, 2006
According to the company, Exubera is the first noninjectable, inhalable form of insulin to be approved since the discovery of insulin in the 1920s, and represents a major advance in diabetes treatment.
According to the World Health Organization, diabetes has reached epidemic proportions and affects approximately 48 million people in Europe alone. People with diabetes often suffer from debilitating complications due to uncontrolled blood sugar levels including heart disease, amputation, blindness, and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2006-02-20)
More Articles from Diabetes Week
- Diabetes Pathogenesis
In hospitalized patients, subclinical hypercortisolism is associated with type 2 diabetes - Diabetes Therapy
FK614, a novel PPAR gamma modulator, has potential antidiabetic properties - Diabetes Therapy
New peptide from Squalus mitsukurii liver shows antidiabetic properties in mice - Diabetes Therapy
Nonthiazolidinedione PPAR gamma agonist reverses endothelial dysfunction in diabetic mice - Type 2 Diabetes
Atorvastatin lowers plasma LDL cholesterol and CRP in type 2 diabetics - Adipose Tissue
PPARalpha regulates the limiting step in fatty acids oxidation in liver mitochondria - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
